We believe, expect and pioneer…

Based on our ultimate spirit, GBC develops new drug candidates through our solid footstone and promotes health by promising and more effective medications for oncological, autoimmune, degenerative, metabolic and orphan diseases etc. We dedicate to advancing health and welfare in whole life.

R&D and Clinical Pipelines

Alzheimer’s disease Pre-Clinical Study Pipeline

Golden Biotechnology Corporation (GBC) was named the winner of the Advance Queensland – Johnson & Johnson Innovation QuickFire Challenge in 2016. GBC authorized Queensland University of Technology (QUT) to operate a pre-clinical test, “Antroquinonol testing in an animal model for Alzheimer’s disease- preventive, therapeutic and biomarker animal studies” and executed Research Services Agreement with QUT in 2017. The studies are expected to complete in 2019Q2.

Hepatitis B Clinical Study Pipeline

Golden Biotechnology Corporation (GBC) cooperated with Chung Shan Medical University Hospital to initiate a phase II clinical trial, “A randomized, double-blind, dosing-ranging, placebo-controlled trial of Antroquinonol in patients with chronic hepatitis B”. The effectiveness verification of the phase II trial is approved by TFDA in May, 2018.

Atopic Dermatitis Clinical Study Pipeline

Golden Biotechnology Corporation (GBC) cooperated with Chung Shan Medical University Hospital to initiate a phase II clinical trial, “A randomized, double-blind, placebo-controlled trial of Antroquinonol in patients with atopic dermatitis”. The phase II trial is approved by TFDA in July, 2018.

Approval for More than 100 patents of Antroquinonol over 45 countries worldwide.

.jpg